Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.

Alaaeldin E, Abu Lila AS, Moriyoshi N, Sarhan HA, Ishida T, Khaled KA, Kiwada H.

Pharm Res. 2013 Sep;30(9):2344-54. doi: 10.1007/s11095-013-1078-4. Epub 2013 May 15.

PMID:
23673556
2.

B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice.

Hashimoto Y, Abu Lila AS, Shimizu T, Ishida T, Kiwada H.

J Control Release. 2014 Jun 28;184:1-8. doi: 10.1016/j.jconrel.2014.04.003. Epub 2014 Apr 13.

PMID:
24727075
3.

Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.

Abu Lila AS, Eldin NE, Ichihara M, Ishida T, Kiwada H.

Int J Pharm. 2012 Nov 15;438(1-2):176-83. doi: 10.1016/j.ijpharm.2012.08.030. Epub 2012 Aug 24.

PMID:
22944302
4.

Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production.

Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H.

J Control Release. 2009 Aug 4;137(3):234-40. doi: 10.1016/j.jconrel.2009.04.006. Epub 2009 Apr 8.

PMID:
19361546
5.

Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.

Abu Lila AS, Doi Y, Nakamura K, Ishida T, Kiwada H.

J Control Release. 2010 Mar 3;142(2):167-73. doi: 10.1016/j.jconrel.2009.10.020. Epub 2009 Oct 25.

PMID:
19861140
6.

Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA.

Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H.

J Control Release. 2011 Apr 30;151(2):149-54. doi: 10.1016/j.jconrel.2010.12.013. Epub 2011 Jan 9.

PMID:
21223988
7.
8.

Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.

Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K.

Int J Pharm. 2008 Jan 4;346(1-2):143-50. Epub 2007 Jun 16.

PMID:
17640835
9.

Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery.

Ichihara M, Moriyoshi N, Lila AS, Ishida T, Kiwada H.

Methods Mol Biol. 2013;948:35-47. doi: 10.1007/978-1-62703-140-0_4.

PMID:
23070762
10.

Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.

Nakamura H, Doi Y, Abu Lila AS, Nagao A, Ishida T, Kiwada H.

Eur J Pharm Biopharm. 2014 May;87(1):142-51. doi: 10.1016/j.ejpb.2013.12.007. Epub 2013 Dec 17.

PMID:
24361534
11.

Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.

Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H.

J Control Release. 2009 Jul 1;137(1):8-14. doi: 10.1016/j.jconrel.2009.02.023. Epub 2009 Mar 12.

PMID:
19285528
12.

Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.

Nagao A, Abu Lila AS, Ishida T, Kiwada H.

Int J Pharm. 2013 Jan 30;441(1-2):395-401. doi: 10.1016/j.ijpharm.2012.11.015. Epub 2012 Nov 19.

PMID:
23174409
13.

Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?

Abu Lila AS, Okada T, Doi Y, Ichihara M, Ishida T, Kiwada H.

Int J Pharm. 2012 Apr 15;426(1-2):263-70. doi: 10.1016/j.ijpharm.2012.01.046. Epub 2012 Jan 30.

PMID:
22310465
14.

Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.

Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H.

J Control Release. 2009 Feb 20;134(1):18-25. doi: 10.1016/j.jconrel.2008.10.018. Epub 2008 Nov 5.

PMID:
19010364
15.

Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.

Hashimoto Y, Shimizu T, Mima Y, Abu Lila AS, Ishida T, Kiwada H.

Toxicol Appl Pharmacol. 2014 May 15;277(1):30-8. doi: 10.1016/j.taap.2014.03.002. Epub 2014 Mar 12.

PMID:
24632081
16.

Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma.

Yang C, Liu HZ, Fu ZX, Lu WD.

BMC Biotechnol. 2011 Mar 15;11:21. doi: 10.1186/1472-6750-11-21.

17.

Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.

Doi Y, Okada T, Matsumoto H, Ichihara M, Ishida T, Kiwada H.

Cancer Sci. 2010 Nov;101(11):2470-5. doi: 10.1111/j.1349-7006.2010.01678.x.

18.

Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production.

Hashimoto Y, Uehara Y, Abu Lila AS, Ishida T, Kiwada H.

Gene Ther. 2014 Jun;21(6):593-8. doi: 10.1038/gt.2014.32. Epub 2014 Apr 3.

PMID:
24694537
19.

PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner.

Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H.

J Control Release. 2007 Oct 8;122(3):349-55. Epub 2007 May 21.

PMID:
17610982
20.

Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.

Abu Lila AS, Uehara Y, Ishida T, Kiwada H.

J Pharm Sci. 2014 Feb;103(2):557-66. doi: 10.1002/jps.23823. Epub 2013 Dec 17.

PMID:
24347396

Supplemental Content

Support Center